AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

AbbVie stock heads toward October 30 results after 10.2 percent growth

Dividend Earnings report AI-generated analysis

πŸ“ˆ AbbVie reported Q2 revenue of USD 16.99 billion, marking a significant 10.2% year-over-year growth.

πŸ’° Adjusted diluted EPS increased by 22.9% to reach USD 3.65 in the second quarter.

πŸš€ Newer medicines Skyrizi and Rinvoq are successfully offsetting revenue pressure from legacy products.

πŸ“… The company is scheduled to release third-quarter 2026 results before the market opens on October 30.

🎯 Analysts maintain a Moderate Buy consensus with an average one-year price target of USD 272.66.

⚠️ Investors are closely monitoring the early commercial outlook for Juvmo as a key growth driver.

πŸ“‰ The stock faces potential pressure from ongoing Humira erosion and increasing market competition.

πŸ’΅ AbbVie's market capitalization stands at USD 464.3 billion as of October 2, 2026.

πŸ₯ The company operates in the Healthcare sector specifically within Drug Manufacturers - General.

Bullish Signals
  • AbbVie achieved a robust 10.2% year-over-year revenue growth to USD 16.99 billion in Q2, demonstrating strong top-line expansion.
  • Adjusted diluted EPS surged by 22.9% to USD 3.65, highlighting significant profitability improvements and operational efficiency.
  • The company successfully leverages newer medicines like Skyrizi and Rinvoq to offset declining revenue from legacy products.
  • Analysts maintain a Moderate Buy consensus with an average price target of USD 272.66, indicating confidence in future performance.
Risk Factors
  • The company faces ongoing revenue pressure due to the erosion of its blockbuster drug Humira as patent protection wanes.
  • Increasing competition in the therapeutic areas where AbbVie operates poses a risk to maintaining current growth trajectories.
  • Investors are scrutinizing the early commercial outlook for Juvmo, which must build sufficient demand to meet expectations.
Full Analysis
AbbVie Inc. reported strong second-quarter financial performance with revenue reaching USD 16.99 billion, representing a 10.2% increase year-over-year. Adjusted diluted earnings per share (EPS) surged by 22.9% to USD 3.65, driven by the successful commercialization of newer medicines like Skyrizi and Rinvoq which are effectively offsetting revenue pressure from legacy products. The company is currently under direct investor scrutiny regarding its post-Humira growth strategy as it approaches the release of third-quarter 2026 results on October 30. Analysts view this upcoming quarter as a critical checkpoint to evaluate the early commercial outlook for Juvmo and the continued execution capabilities required to manage Humira's patent erosion and competitive landscape. Market sentiment remains cautiously optimistic with a Moderate Buy consensus from 31 brokerages, including multiple Strong Buy ratings. The average one-year price target of USD 272.66 sits 3.75% above the recent trading price, reflecting confidence in AbbVie's ability to navigate its transition while maintaining robust financial metrics and delivering on strategic growth targets.